Integra Lifesciences Holdings (IART) Non-Current Debt (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Non-Current Debt data on file, last reported at $716.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 36.48% year-over-year to $716.9 million; the trailing twelve-month figure through Mar 2026 stood at $716.9 million (down 36.48% YoY), and the FY2025 full-year result was $1.7 billion, up 58.98% from the prior year.
• Non-Current Debt eased to $716.9 million in Q1 2026, from $1.7 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $1.7 billion in Q4 2025 to a low of $716.9 million in Q1 2026.
• A 5-year average of $913.4 million and a median of $814.5 million in 2022 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt soared 58.98% in 2025 and slumped 36.48% in 2026, its largest moves.
• Tracing IART's Non-Current Debt over 5 years: stood at $733.1 million in 2022, then advanced by 12.61% to $825.6 million in 2023, then surged by 31.78% to $1.1 billion in 2024, then surged by 58.98% to $1.7 billion in 2025, then sank by 58.55% to $716.9 million in 2026.
• Business Quant data shows IART's Non-Current Debt at $716.9 million in Q1 2026, $1.7 billion in Q4 2025, and $736.2 million in Q3 2025.